The Right Drug or Trial for Every Patient. This is the OmniSeq Mission.

OmniSeq® was founded with one purpose in mind: To inform physicians and their patients of the most actionable tumor-profiling information possible. We know that, when we accomplish this goal, we’re enabling patients to benefit from personalized treatment that will help them fight their illness at a molecular level.

At Omniseq®, we advance personalized medicine by focusing solely on the improvement of patient outcomes.

This is Who We Are.

Founded in 2015, OmniSeq® is a commercial, CAP accredited, CLIA and New York State CLEP licensed clinical laboratory in Buffalo, New York. We utilize next generation sequencing (NGS) technologies through New York State CLEP approved comprehensive molecular profiling, as well as offer a wide variety of pharmaceutical services to assist in drug development.

This is Our Legacy.

Roswell Park Comprehensive Cancer Center in Buffalo, New York is a pioneer clinical research facility for advanced treatment of all forms of adult and pediatric cancer, and a Member of the National Comprehensive Cancer Network. Roswell Park Comprehensive Cancer Center’s Founder, Dr. Roswell Park, sought to cure cancer and advocated a close connection between laboratory and clinical research to speed up discovery, and Roswell Park Comprehensive Cancer Center was the first institution to focus exclusively on cancer research.

After more than a century, Roswell Park Comprehensive Cancer Center continues to be at the forefront of groundbreaking cancer research. The institute’s history includes initiating the first experiments in chemotherapy in 1904; becoming America’s first Comprehensive Cancer Center; and providing the source, RP11 (RP stands for Roswell Park), for much of the BAC clone library used in the Human Genome Project.

OmniSeq® emerged from the Roswell Park Comprehensive Cancer Center’s Center of Personalized Medicine, and the breakthrough research, scientific expertise, and commitment to improving patient care define what OmniSeq® is today.

Dr. Carl Morrison, Founder of OmniSeq® and Executive Director of the Center for Personalized Medicine at Roswell Park Comprehensive Cancer Center, first envisioned the role of more advanced bioinformatics in clinical decision support while working at Roswell Park.

OmniSeq Clinical Team

Carl Morrison, MD, DVM

President, CMO, Laboratory Director and Founder

Dr. Morrison is OmniSeq’s Founder and Chief Medical Officer. Dr. Morrison is a board-certified pathologist and Executive Director of the Center for Personalized Medicine at Roswell Park Comprehensive Cancer Center in Buffalo, New York. Dr. Morrison is a Professor and Program Member in Cancer Genetics at Roswell Park Comprehensive Cancer Center and was awarded Roswell Park’s prestigious Thomas B. Tomasi Hope Award for his contribution to cancer research.

Antonios Papanicolau-Sengos, MD

Clinical Laboratory Director

Dr. Papanicolau-Sengos became the Clinical Laboratory Director at OmniSeq after transitioning from Roswell Park Comprehensive Cancer Center. He oversees the implementation of clinical testing and signs the bulk of the clinical assays performed at OmniSeq. He has extensive experience with current molecular techniques such as nCounter and next-generation sequencing technologies. As Clinical Laboratory Director he also manages day-to-day laboratory operations and regulatory compliance.

Jeffrey Conroy

Jeffrey Conroy

Chief Scientific Officer

Jeffrey Conroy serves as Chief Scientific Officer for OmniSeq. He oversees the scientific functions of OmniSeq, including Research and Development (R&D), Bioinformatics and Information Technology.  He leads business development activities with key industry and pharmaceutical partners, and oversees the development and implementation of advanced diagnostic tests from target design through analytical validation.  Prior to joining OmniSeq, Jeff spent three years as Director of Genomic Technologies in the Center for Personalized Medicine at Roswell Park Comprehensive Cancer Center.

OmniSeq Executive Team

Margot Schoenborn

Chief Executive Officer

Margot Schoenborn serves as Chief Executive Officer and a member of the Board of Directors.  She is responsible for leading corporate strategy and oversight of all commercial and corporate functions, while partnering with the Company’s President & CMO and Chief Scientific Officer to enable OmniSeq

to realize the potential of its genomic testing and next-generation sequencing (NGS) assays in clinical and research settings.  She also serves at the Company’s General Counsel and Corporate Secretary.  Margot has experience in corporate development, capital planning, transactions, capital markets activities, corporate finance, and leadership of multi-functional teams over a nearly 20-year career in healthcare, law enforcement, and commercial litigation.  Prior to being appointed CEO in 2019, Margot was the Company’s Chief Administrative Officer and General Counsel, where she served as advisor to the Chairman, CEO and Board on governance, executive compensation, strategic alliances, and capital planning, including Series B fundraising activities that secured investments from leading global life sciences and technology companies. As CAO, she was responsible for OmniSeq’s finance, managed care, billing, HR, customer service, risk management, compliance and legal functions. 

Mary K. Nesline

Senior Vice President of Knowledge Informatics

Mary Nesline is SVP of Knowledge Informatics at OmniSeq, a precision medicine molecular diagnostics company in Buffalo, NY. Mary leads clinical evidence development and management, as well as integration with bioinformatics and information technology for product design and delivery.

Keith DiPirro

Executive Director, Sales

Keith DiPirro leads commercial operations as OmniSeq’s Executive Director of Sales. With over 18 years in the medical sales industry, Keith heads up sales operations for OmniSeq and leads the sales efforts in collaboration with OmniSeq’s exclusive channel partner.

Keith has won numerous sales awards throughout his professional career that spans across the medical device and pharmaceutical industries.

Yirong Wang

Executive Director, Bioinformatics and IT

Yirong Wang leads bioinformatics development, information technology infrastructure and software development for OmniSeq clinical and research products.

Daria Shanchuk, CPA, MBA

Executive Director, Finance

Daria Shanchuk leads the finance and budgeting functions for OmniSeq and has over 20 years of accounting and management experience.

Sean Glenn

Vice President of Clinical and Research Development

Dr. Glenn is responsible for leadership of the R&D staff which is responsible for identifying and developing the next level of clinical tests needed to service the oncology field.

OmniSeq Board of Directors

Mark Gardner, MBA

Senior Vice President, Corza Health

Mark Gardner is the Senior Vice President of Business Development for Corza Health. Prior to this role Mark served as the Chief Executive Officer of OmniSeq. Mark has spent over twelve years in various executive roles at Thermo Fisher Scientific (previously Life Technologies).

Mark was the Vice President and General Manager of the Ion Torrent business unit at Thermo Fisher. Prior to Thermo Fisher, Mark was a Six Sigma Master Black Belt at General Electric, an entrepreneur at two start-up companies, a management consultant at McKinsey and Company, and a Navy Pilot.

Kenneth A. Manning

Kenneth A. Manning is a partner with Phillips Lytle LLP, with experience in corporate litigation, personal injury litigation and class actions that is represented by his status as member emeritus for the Dean’s Advisory Council of University at Buffalo Law School.

Carl Morrison, MD, DVM

President, CMO, Laboratory Director and Founder

Carl Morrison is a board-certified pathologist, who developed the vision for OmniSeq while leading the Center for Personalized Medicine and Division of Molecular Pathology at RPCCC.

Marcia Eisenberg, PhD

Marcia Eisenberg, PhD is Chief Scientific Officer and Senior Vice President at LabCorp Diagnostics. Dr. Eisenberg earned a BS in biology, a BA in psychology, and an MS in molecular biology from the State University of New York at Albany. She completed her PhD in molecular biology from the University of Kentucky.

Steven M. Anderson, PhD

Chief Scientific Officer-Covance, Sr VP, LabCorp

Dr. Anderson is a Senior Vice President at Laboratory Corporation of America (LabCorp), and the Chief Scientific Officer for the Covance Drug Development business of LabCorp. He has been with the LabCorp organization for 26 years and has held a variety of positions including Director of Operations for ViroMed Laboratories, Director of Operations for Monogram Biosciences, Director of Operations for the Center for Molecular Biology and Pathology, Director of Operations for Integrated Oncology and Genetics, National Director of Research and Development, and Global Head of LabCorp Clinical Trials. Dr. Anderson is a member of a variety of professional societies including the American Association for Cancer Research, the American Society of Clinical Oncology and the Association for Molecular Pathology.



Paul Billings, MD, Ph.D, FACP, FACGMP

Paul Billings, MD, Ph.D, FACP, FACGMP is a Board certified internist and clinical geneticist. Dr. Billings is the Chairman of Biological Dynamics, Inc., an innovative cancer testing company in San Diego, CA and is also the CMO of Natera.

Buford Sears

Buford Sears is KeyBank N.A. Regional President and divisional manager for WNY, in charge of commercial lending in WNY and Western Pennsylvania, Roswell Park Comprehensive Cancer Center Board Member, Chair Roswell Park Comprehensive Cancer Center Finance Committee, with expertise in commercial real estate equipment financing, as well as healthcare and government banking activities.